G1 Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview

G1 Therapeutics

06/08/2024 19:33

* G1 Therapeutics Inc  GTHX.OQ   GTHX.O  is expected to show
a
fall in quarterly revenue when it reports  results on August 8
for the period ending June 30 2024
    * The Research Triangle Park North Carolina-based  company
is
expected to report a 61.4% decrease in revenue to $16.363
million from $42.39 million a year ago, according to the mean
estimate from 6 analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for G1 Therapeutics Inc is
for a
loss of 17 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for G1
Therapeutics
Inc is $4.50​, above​ its last closing price of $3.95. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.21       -0.21      -0.20     Beat    2.7
 Dec. 31 2024  -0.28       -0.28      -0.21     Beat    23.7
 Sep. 30 2023  -0.32       -0.33      -0.35     Missed  -6.4​
 Jun. 30 2023  -0.11       -0.22      0.14      Beat    164
 ​​Jan.        -0.62       -0.64      -0.53     Beat    17.2
 1 0001                                                 
 Dec. 31 2022  -0.84       -0.84      -0.73     Beat    13.5​
 Sep. 30 2022  -0.61       -0.63      -0.59     Beat    6.7
 Jun. 30 2022  -1.02       -1.02      -0.92     Beat    9.7
 This summary was machine generated August 6 at 18:32 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)